Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Mallinckrodt Fell Over 17% Today

By Maxx Chatsko - Aug 27, 2019 at 4:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The bad news keeps piling up.

What happened

Shares of Mallinckrodt (MNK) dropped as much as 17.3% today on multiple news items. The company reported that an appeals court has ruled that patents covering INOmax, the company's inhaled nitric oxide product, were not infringed upon by competing drug Noxivent from Praxair. That wasn't all.

On Monday, news broke that a judge in Oklahoma had ordered Johnson & Johnson to pay $572 million for its role in the opioid crisis in the state. That wasn't quite the $17 billion that state prosecutors had sought, but it was more than the $270 million paid by Purdue Pharma and the $85 million paid by Teva Pharmaceuticals earlier this year.

Mallinckrodt is also listed in lawsuits stemming from the opioid crisis in states across the country. Investors are transitioning from optimism to pessimism about how the company will fare in court. As of 3:38 p.m. EDT, the stock had settled to a 14.7% loss.

Multiple declining lines and arrows on a chalkboard.

Image source: Getty Images.

So what

Investors are right to be a least a little worried about encroaching competition for INOmax, which generated $291 million in net sales, or 18% of Mallinckrodt's total revenue, in the first half of 2019. It doesn't help that the company's lead drug brand, Acthar Gel, has seen sales decline 9% in the last year. 

Falling drug sales is an unwelcome trend in any environment, but doubly so given the uncertainty surrounding the pending opioid litigation. That uncertainty forced Mallinckrodt to suspend plans to spin off its specialty pharmaceutical division, which is responsible for 76% of revenue in the first half of 2019, earlier this month.

Now what

Few things can sabotage a business as quickly as uncertainty -- and Mallinckrodt has multiple sources of it. Case in point: Its shares have fallen 90% in the last year. Until more is known about the specific financial responsibility the company will bear in the opioid crisis, investors can expect plenty of volatility.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mallinckrodt Public Limited Company Stock Quote
Mallinckrodt Public Limited Company
MNK
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$8.47 (1.93%) $0.16
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$176.98 (1.75%) $3.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.